Journal
GEROSCIENCE
Volume 43, Issue 3, Pages 1135-1158Publisher
SPRINGER
DOI: 10.1007/s11357-020-00274-1
Keywords
Rapamycin; Aging; Neurodegeneration; Lifespan; Cancer; Heart
Categories
Funding
- NIH [R01AG045693, R01AG057424]
- Department of Veterans Affairs [I01BX004538]
Ask authors/readers for more resources
Rapamycin has shown potential to extend lifespan and treat age-related diseases in mice. Research should continue to focus on the effects of rapamycin in aging physiology and diseases, and bringing it into clinical applications.
In 2009, rapamycin was reported to increase the lifespan of mice when implemented later in life. This observation resulted in a sea-change in how researchers viewed aging. This was the first evidence that a pharmacological agent could have an impact on aging when administered later in life, i.e., an intervention that did not have to be implemented early in life before the negative impact of aging. Over the past decade, there has been an explosion in the number of reports studying the effect of rapamycin on various diseases, physiological functions, and biochemical processes in mice. In this review, we focus on those areas in which there is strong evidence for rapamycin's effect on aging and age-related diseases in mice, e.g., lifespan, cardiac disease/function, central nervous system, immune system, and cell senescence. We conclude that it is time that pre-clinical studies be focused on taking rapamycin to the clinic, e.g., as a potential treatment for Alzheimer's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available